论文部分内容阅读
年龄相关性黄斑变性(AMD)是一种慢性、进展性视力损害性疾病.近年来湿性AMD治疗方面取得巨大进展,接受眼内注射抗血管内皮生长因子A(VEGF-A)治疗的湿性AMD患者数量迅速增加,并在短期内能够有效控制病情,改善视力.随着治疗和随访周期的延长,抗VEGF-A类药物治疗湿性AMD的长期疗效成为患者和医生关注的焦点.本文将概述治疗湿性AMD的常用抗VEGF-A类药物,并对其长期疗效及安全性进行总结,探讨分析长期应用抗VEGF-A类药物影响视力预后的原因.“,”As a progressive chronic disease,age-related macular degeneration (AMD) is the leading cause of blindness worldwide.However,current therapy for AM D shows a dramatic breakthrough.More and more patients with AMD undergo intravitreous injection of anti-vascular endothelial growth factor A (VEGF-A) regimen,which has been demonstrated a beneficial therapeutic treatment to improve visual acuity in a short period.The long-term outcomes have come into focus considering prolonged treatment cycle and follow-up period.The long-term outcomes and safety of anti VEGF-A will be reviewed in this article contributing to investigate the causes influencing prognosis of visual acuity after anti VEGF-A treatment.